Because BQ-mediated APP induction does not require interferon signaling, this strategy may have particular relevance for clinical scenarios in which tumor antigen presentation is dampened by the loss or silencing of cancer cell interferon signaling, which has been demonstrated to confer both intrinsic (Shin et al., 2017) and acquired (Zaretsky et al., 2016) ICB resistance in human melanoma patients. Here, APP is linked to cancer.